MedTrace Logo

Stroke Prevention in Sickle Cell Anemia (STOP 1)

NCT00000592 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-12-23

No results posted yet for this study

Summary

To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.

Conditions

  • Anemia, Sickle Cell
  • Cerebral Embolism and Thrombosis
  • Cerebrovascular Disorders
  • Hematologic Diseases
  • Hemoglobinopathies

Interventions

PROCEDURE

blood transfusion

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Augusta University

    lead OTHER

Principal Investigators

  • Donald Brambilla · New England Research Institute Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Min Age
2 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-07-31
Completion
2000-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000592 on ClinicalTrials.gov